NCT07214857View on ClinicalTrials.gov

Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States

CompletedOBSERVATIONAL
Enrollment

1,385

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

October 9, 2024

Study Completion Date

October 9, 2024

Conditions
Cardiovascular Disease
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY